- Home
- EE vs TSHA Comparison
EE vs TSHA Comparison
Compare EE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- TSHA
- Stock Information
- Founded
- EE 2003
- TSHA 2019
- Country
- EE United States
- TSHA United States
- Employees
- EE N/A
- TSHA N/A
- Industry
- EE Oil/Gas Transmission
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EE Utilities
- TSHA Health Care
- Exchange
- EE Nasdaq
- TSHA Nasdaq
- Market Cap
- EE 786.2M
- TSHA 728.4M
- IPO Year
- EE 2022
- TSHA 2020
- Fundamental
- Price
- EE $24.49
- TSHA $3.00
- Analyst Decision
- EE Buy
- TSHA Strong Buy
- Analyst Count
- EE 7
- TSHA 7
- Target Price
- EE $32.86
- TSHA $8.71
- AVG Volume (30 Days)
- EE 549.8K
- TSHA 2.6M
- Earning Date
- EE 08-11-2025
- TSHA 08-12-2025
- Dividend Yield
- EE 1.31%
- TSHA N/A
- EPS Growth
- EE 18.98
- TSHA N/A
- EPS
- EE 1.33
- TSHA N/A
- Revenue
- EE $987,637,000.00
- TSHA $8,098,000.00
- Revenue This Year
- EE $34.24
- TSHA N/A
- Revenue Next Year
- EE $15.84
- TSHA N/A
- P/E Ratio
- EE $18.33
- TSHA N/A
- Revenue Growth
- EE 9.86
- TSHA N/A
- 52 Week Low
- EE $17.70
- TSHA $1.05
- 52 Week High
- EE $32.99
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- EE 45.64
- TSHA 63.38
- Support Level
- EE $23.28
- TSHA $2.76
- Resistance Level
- EE $24.91
- TSHA $3.05
- Average True Range (ATR)
- EE 0.91
- TSHA 0.15
- MACD
- EE 0.14
- TSHA 0.00
- Stochastic Oscillator
- EE 83.36
- TSHA 75.51
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.